NDAOPHTHALMICSOLUTION/DROPS
Approved
Jan 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISINE is a fixed-dose combination ophthalmic solution containing naphazoline hydrochloride (a decongestant) and pheniramine maleate (an antihistamine) used to relieve eye redness, itching, and discomfort associated with allergic conjunctivitis and minor eye irritation. The naphazoline acts as a vasoconstrictor to reduce redness while pheniramine provides antihistamine relief. This product represents a mature, well-established over-the-counter therapeutic approach for symptomatic eye allergy relief.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team focus shifting toward lifecycle management and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VISINE offers limited career growth given its LOE-approaching status and zero linked job postings, making it primarily a defensive, maintenance-focused role. This assignment is best suited for professionals seeking stability in established product management or those building expertise in generic transition strategies and OTC market dynamics.
Brand ManagerField Sales Representative
Worked on VISINE at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.